NeuMentamin Extended-Release Capsule 24 mg (Galantamine Hydrobromide)

Adult dose

(Adults) Administer once daily in the morning. Administration immediately after breakfast is preferable. Swallow this medicine whole with an adequate amount of water; do not chew or crush it. Ensure adequate fluid intake while taking this medicine. Initial dose: 8 mg once daily is recommended for the first 4 weeks. Maintenance dose: - After the initial dose, administer 16 mg once daily for at least 4 weeks. - Thereafter, the dose may be increased to a maximum of 24 mg daily based on evaluation of clinical benefit, tolerability, etc. - For patients who do not tolerate 24 mg daily or whose response does not improve, consider reducing the dose to 16 mg daily. - This medicine may be continued as long as the patient benefits from treatment. Regularly assess its clinical benefit, and consider discontinuing treatment if there is no therapeutic effect. - No rebound phenomenon occurs after discontinuation of treatment (e.g., in preparation for surgery). (Patients with renal or hepatic impairment) Plasma concentrations of galantamine may increase in patients with moderate to severe renal or hepatic impairment. For patients with moderate hepatic impairment, based on pharmacokinetic modeling, administer 8 mg every other day for at least 1 week; morning administration is preferable. Thereafter, administer 8 mg once daily for at least 4 weeks. Do not exceed 16 mg daily. This medicine is contraindicated in patients with severe hepatic impairment (Child-Pugh score >9). No dosage adjustment is necessary in patients with mild hepatic impairment. No dosage adjustment is necessary in patients with creatinine clearance of 9mL/min or greater. This medicine is contraindicated in patients with severe renal impairment (creatinine clearance < 9mL/min). (Concomitant therapy) Consider reducing the dose of this medicine in patients receiving CYP 2D6 or CYP 3A4 inhibitors (e.g., ketoconazole).

Child dose

Use in children is not recommended.

This medication should not be administered to patients who are allergic to any of its components, or those with severe liver or kidney impairment. Caution should be exercised when using this medication in patients who are sensitive to the dye, Yellow No. 5. Side effects such as nausea, vomiting, diarrhea, headache, dizziness, drowsiness, and bradycardia may occur during use; it is important to consult healthcare professionals if these symptoms arise. Particular caution is advised for patients with cardiac diseases or a history of slow heart rates, as well as those with gastrointestinal disorders when using this medication. This medication should also be administered carefully in patients with severe asthma or chronic obstructive pulmonary disease, and in those with bladder dysfunction. Pregnant women should carefully weigh the risks to the fetus against the benefits of this medication, and breastfeeding mothers are advised not to take this medication. As this medication may cause drowsiness or dizziness, caution is required while driving or operating machinery. In case of overdose, symptoms such as nausea, vomiting, bradycardia, and seizures may occur; therefore, it is necessary to seek appropriate treatment at a healthcare facility immediately. This medication should not be used in conjunction with other cholinergic agents, and interactions may occur with certain heart medications, antifungals, and antidepressants, so it is crucial to inform healthcare professionals of any other medications being taken. Keep out of reach of children and do not transfer to other containers for safety.

Loss of appetite, depression, dizziness, headache, tremors, fainting, drowsiness, sedation, bradycardia, nausea, vomiting, diarrhea, abdominal pain, upper abdominal pain, indigestion, abdominal discomfort, muscle cramps, fatigue, asthenia, lethargy, weight loss, falls, lacerations, dehydration, dysgeusia, hypersomnia, sensory disturbances, blurred vision, I degree atrioventricular block, palpitations, sinus bradycardia, ventricular premature contractions, flushing, hypotension, nausea, sweating, muscle weakness, hypersensitivity, hallucinations, visual hallucinations, auditory hallucinations, convulsions, tinnitus, complete heart block, hypertension, hepatitis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, erythema multiforme, elevated liver enzymes, dizziness, rash, itching, extrapyramidal syndrome, Parkinson's syndrome, exacerbation of Parkinson's syndrome, hand paralysis, bradykinesia, pica syndrome, delirium, sweating, edema, constipation, thirst, gastritis, belching, jaundice, elevated γ-GT, elevated ALT/AST, exacerbation of chronic renal failure, urinary incontinence, drowsiness, muscle weakness, gastrointestinal cramping, drooling, tearing, defecation, urination, collapse, bronchial hypersecretion, bronchospasm, Torsades de Pointes, prolonged QT interval, ventricular tachycardia, brief loss of consciousness

This medication should be stored in a tightly sealed container to prevent air exposure, ideally at room temperature between 1°C and 30°C. Proper storage helps maintain the medication's efficacy over time.

Appearance

An opaque light brown hard capsule containing white to almost white extended-release pellets.

Package unit

30 capsules/bottle